Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31666014 | 0.84 | GABRG2 (0.41) | GABRG2GABRB3GABRA5HPGDKDM4E | |
| SCHEMBL18941218 | 0.84 | CDK1 (0.49) | GABRG2GABRB3GABRA5GAASMN1; SMN2 | |
| SCHEMBL21731846 | 0.84 | GABRG2 (0.41) | GABRG2GABRB3GABRA5HPGDKDM4E | |
| SCHEMBL8673753 | 0.83 | HTR6 (0.43) | HTR6ESR2GABRG2GABRB3GABRA5 | |
| SCHEMBL8673748 | 0.82 | PTGS1 (0.60) | HTR6MAPTKDM4ECYP1A2CYP2D6 | |
| SCHEMBL18906765 | 0.80 | AKR1C3 (0.38) | GABRG2GABRB3GABRA5LMNAGABRA1 | |
| SCHEMBL27985045 | 0.80 | CHRM2 (0.50) | HTR6ESR2GABRG2GABRB3GABRA5 | |
| SCHEMBL16741688 | 0.79 | GAA (0.50) | ESR2HPGDMAPTGAAKDM4E | |
| SCHEMBL17444720 | 0.76 | AKR1C3 (0.40) | GABRG2GABRB3GABRA5HPGDNPSR1 | |
| SCHEMBL18966700 | 0.75 | ESR2 (0.43) | HTR6ESR2GABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166555-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | NOVOGEN LIMITED (AU) | 2017-06-15 | — | — | US | disclosed |
| US-20170166555-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | NOVOGEN LIMITED (AU) | 2017-06-15 | — | — | US | disclosed |
| US-20170152226-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2017-06-01 | — | — | US | disclosed |
| US-20170152226-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2017-06-01 | — | — | US | disclosed |
| US-20170152226-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2017-06-01 | — | — | US | disclosed |
| CN-106661005-A | Functionalized and substituted indoles as anticancer agents | 诺沃根公司 | 2017-05-10 | — | — | CN | disclosed |
| WO-2016187667-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | NOVOGEN LIMITED (AU) | 2016-12-01 | — | — | WO | disclosed |
| CN-105916841-A | Functionalised and substituted indoles as anti-cancer agents | 诺沃根公司 | 2016-08-31 | — | — | CN | disclosed |
| WO-2016008011-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2016-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166555-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | TPM3, TPM4, TNNI3 | HTR6 980/4885ESR2 3685/4885GABRG2 4443/4885 |
| US-20170152226-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | TPM3, TPM4, TNNI3 | HTR6 910/4885ESR2 3514/4885GABRG2 4325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.